Anti-GITR immunotherapy-induced tumor-specific Th9 cells, which are highly effective in eradicating advanced tumors in vivo, display a unique hyperproliferative feature driven by the Pu.1-TRAF6-NF-κB axis (340, 341). The gene discussed is NFKB1; the disease is neoplasm.